General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Alynylam Pharmaceuticals(MODEST), Bayer Healthcare Pharmaceuticals(MODEST), Novartis Corporation(MODEST), Regeneron Pharmaceuticals(MODEST), ARMGO Pharmaceuticals(MODEST), Medscape/Heart Org.(MODEST), AnaCardio(MODEST), AstraZeneca Pharmaceuticals(MODEST), Cardurion(MODEST), Cytokinetics(MODEST), River BioMedics(MODEST), Biohaven Pharma.(MODEST), Chugai Pharma.(MODEST), Protherics Medicine Developments Ltd.(MODEST), DalCor Pharma.(MODEST) SPEAKER'S BUREAU: Alkem Metabolics(MODEST), AstraZeneca Pharmaceuticals(MODEST), Canadian Medical and Surgical Knowledge(MODEST), Emcure Pharmaceuticals Ltd.(MODEST), Eris Lifesciences(MODEST), Hikma Pharmaceuticals(MODEST), Imagica Health(MODEST), Intas Pharmacueticals(MODEST), J.B. Chemicals & Pharmaceuticals Ltd.(MODEST), Lupin Pharmaceuticals, Inc(MODEST), ProAdWise Communications(MODEST), Radcliffe Cardiology(MODEST), Sun Pharmaceuticals(MODEST), Translational Medicine Academy(MODEST), At the Limits Ltd.(MODEST), IMEDIC Pharma. Micro Labs. Ltd.(MODEST), Hilton Pharma.(MODEST), MCI India(MODEST), Centrix Healthcare(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Novartis Corporation(SIGNIFICANT) OTHER FINANCIAL BENEFIT: AstraZeneca Pharmaceuticals(SIGNIFICANT), Cardurion(MODEST), Cytokinetics(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(MODEST), Global Clinical Trial Partners Ltd. (GCTP)(SIGNIFICANT), Roche Pharma.(SIGNIFICANT), Alynylam Pharma.(MODEST), British Heart Foundation(SIGNIFICANT), National Institute for Health – National Heart Lung and Blood Institute (NIH-NHLBI), (SIGNIFICANT)

View Full Disclosure